読み込み中
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
最新データ
$6.65
+$0.60 · +9.92%
日中の時刻はETです。市場データは遅延する場合があります。
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
28
割高
センチメント
52
まちまち
リスク
82
極めて高いリスク
モメンタム
18
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 203.67万 USD | 214万 USD | 208.53万 USD | 207.96万 USD | 142.22万 USD |
| 売上原価 | 147.03万 USD | 144万 USD | 122.32万 USD | 132.92万 USD | 91.78万 USD |
| 粗利益 | 56.63万 USD | 69.93万 USD | 86.21万 USD | 75.04万 USD | 50.43万 USD |
| 研究開発 | 189.11万 USD | 311.9万 USD | 196.04万 USD | 98.22万 USD | 41.14万 USD |
| 販売・一般管理 | 699.31万 USD | 427万 USD | 377.36万 USD | 391.6万 USD | 402.28万 USD |
| 営業費用 | 888.43万 USD | 738.9万 USD | 573.4万 USD | 489.83万 USD | 443.42万 USD |
| 受取利息 | — | 19.17万 USD | 1.69万 USD | — | — |
| 支払利息 | 2.25万 USD | 2.14万 USD | 7.58万 USD | 8289 USD | 11.84万 USD |
| 減価償却費と償却費 | 19.38万 USD | 28.51万 USD | 28.77万 USD | 36.9万 USD | 31.83万 USD |
| 営業利益 | −831.8万 USD | −669万 USD | −487.19万 USD | −414.79万 USD | −392.99万 USD |
| 純利益 | −822.96万 USD | −1048.3万 USD | −548.53万 USD | −481.08万 USD | −842.24万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2022年8月12日 | 583:500 | — | — |
株式分割 | 2019年7月24日 | 1:4 | — | — |
発効済み 2022年8月12日
583:500
発効済み 2019年7月24日
1:4
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
